Lomitapide Mesylate and Tafamidis

• Generic Name: lomitapide
• Dosage Forms: n.a.
• Other Brand Names: Juxtapid

Adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce LDL-cholesterol, total cholesterol, apolipoprotein B (apo B), and non-HDL-cholesterol concentrations in the management of homozygous familial hypercholesterolemia (designated an orphan drug by US FDA for use in this condition).

Safety and efficacy not established in patients with hypercholesterolemia who do not have homozygous familial hypercholesterolemia.

Effects on cardiovascular morbidity and mortality not established.

• Generic Name: tafamidis
• Dosage Forms: n.a.
• Other Brand Names: Vyndamax, Vyndaqel

Tafamidis affects a protein called transthyretin (TTR, made primarily in the liver). Transthyretin-mediated amyloidosis (ATTR) is a condition in which abnormal deposits of TTR protein build-up in many parts of the body, interfering with normal function. A build-up of TTR in the heart can lead to heart failure.

People with hereditary ATTR amyloidosis have a DNA mutation that can be passed from one generation to the next. People with wild-type ATTR amyloidosis do not have abnormal DNA and cannot pass on the condition.

Tafamidis is used in adults with hereditary or wild type ATTR to treat cardiomyopathy (damage of the heart muscle) caused by a build-up of TTR.

Tafamidis may also be used for purposes not listed in this medication guide.